RegenXBio (RGNX) Gets a Buy from RBC Capital
RBC Capital analyst Luca Issi maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $30.00. The ...
Arcus Biosciences names Richard Markus chief medical officer
Arcus Biosciences (RCUS) announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer effective January 31, 2025. Dr.